Clinical trial · Interventional
Additive Homeopathy in Cancer Patients
Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Study Evaluating Quality of Life in Patients With Advanced Malignant Lung Tumors With or Without "add-on" Homeopathy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators aim to investigate the validity of their previous results in a randomized prospective, placebo-controlled, double-blind, multicenter controlled evaluation of questionnaires in patients with advanced malignant tumors. The investigators plan to compare the treatment outcome (quality of life and survival) in tumor patients, receiving standard or "add-on" homeopathic treatment. The null hypothesis is that "add-on" homeopathic treatment does not create a benefit for cancer patients. In addition the investigators evaluate survival time.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Tumors | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Additive classical homeopathy | Drug | — | UNRESOLVED |
| Homeopathic Placebo globules | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Additive homeopathy in cancer patients
- description
- Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
- interventionNames
- Drug: Additive classical homeopathy
- type
- PLACEBO_COMPARATOR
- label
- Additive homeopathic placebo globules
- description
- Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
- interventionNames
- Drug: Homeopathic Placebo globules
- type
- NO_INTERVENTION
- label
- No intervention
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Informed consent * Clinical diagnosis of advanced tumor stages of non small-cell lung carcinoma (NSCLC) IIIB, IIIC, IV. Exclusion Criteria: * sensitizing mutation of the EGFR gene or translocation of the ALK gene * refusal to sign informed consent * pregnancy * hematological, hepatic, or renal pathology * coronary heart disease * history of secondary tumor * major surgery within 4 weeks prior to study entry * active infection and symptomatic peripheral neuropathy * central nervous system metastases unless the metastases were treated and stable * active autoimmune disease * use of systemic immunosuppressive treatment * use of systemic treatment during the previous 2 years * active interstitial lung disease, or a history of pneumonitis for which glucocorticoids were prescribed * previous systemic therapy for metastatic disease or previous irradiation * use of any complementary and/or alternative therapy, including homeopathy other than the research treatment during the trial
References
Publications (1)
- DERIVEDFrass M, Lechleitner P, Grundling C, Pirker C, Grasmuk-Siegl E, Domayer J, Hochmair M, Gaertner K, Duscheck C, Muchitsch I, Marosi C, Schumacher M, Zochbauer-Muller S, Manchanda RK, Schrott A, Burghuber O. Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study. Oncologist. 2020 Dec;25(12):e1930-e1955. doi: 10.1002/onco.13548. Epub 2020 Nov 7. PMID 33010094